AMF Tjanstepension 13F: Cuts Gilead Sciences (GILD) Stake by $78M

In a Form 13F filing on October 22, 2026, AMF Tjanstepension reported a major reduction in its Gilead Sciences, Inc. (GILD) holdings. The fund cut its stake by 96.1%, selling 521,261 shares during the period. That left the institution holding just 21,001 shares, valued at approximately $3,130,199 as of the reporting date.

GILD Gilead Sciences, Inc.

$156.70 ▲ +31.18% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside AMF Tjanstepension's Gilead Trade

AMF Tjanstepension went from holding 542,262 shares down to a much smaller position of 21,001 shares. The dramatic decrease reflects a sharp pullback by the fund on the biopharmaceutical company during the quarter.

Gilead Sciences, Inc. Stock Down 1.7%

Gilead recently traded around $153.57 as of October 22, 2026. The stock sits above its 50-day moving average of $147.23 and well above its 200-day moving average of $138.18. Shares rest below the 52-week high of $160.51 and well above the 52-week low of $114.02.

Recent Earnings

Gilead generated $30.46 billion in trailing twelve-month revenue. The firm posted a trailing twelve-month loss with earnings per share at -$2.65, alongside a net profit margin of -10.6% and a return on equity of -20.7%. The company's next earnings report is scheduled for October 29, 2026.

Dividend

Gilead Sciences pays an annual dividend rate of $3.28 per share, giving it a dividend yield of 2.14%. The payout ratio stands at 43.5%.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders completed several transactions in late summer. On August 26, 2026, Director Anthony Welters disposed of 18,000 shares worth $2,675,220. CEO Daniel Patrick O'Day sold 15,000 shares valued at $2,229,592 on September 1, 2026. CFO Andrew D Dickinson parted with 3,000 shares at $145.29 per share for a total of $435,870 on September 15, 2026. Officer Johanna Mercier also sold 3,000 shares worth $432,646 on September 15, 2026.

Analysts Set New Price Targets

Wall Street firms updated their views on Gilead ahead of the autumn reporting cycle. On October 7, 2026, Truist Securities maintained its buy rating and raised its price target from $150.00 to $158.00. JP Morgan maintained an overweight rating on October 7, 2026, boosting its target from $160.00 to $170.00. RBC Capital maintained a sector perform rating on October 8, 2026, nudging its target from $123.00 to $126.00. Cantor Fitzgerald reiterated an overweight rating on October 8, 2026, keeping its target at $155.00. B of A Securities maintained a buy rating on October 20, 2026, increasing its target from $168.00 to $172.00. Overall, the stock holds a consensus buy rating with a mean price target of $160.15 across 26 analyst opinions.

About Gilead Sciences

Gilead Sciences, Inc. is a Foster City, California-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for severe and unmet medical needs. The company develops treatments for conditions such as HIV-1 infection, featuring well-known medications like Biktarvy and Descovy.

Bottom Line

Investors will look closely at Gilead's upcoming earnings release on October 29, 2026, for updated financial metrics. Future institutional filings will show whether other large investors follow AMF Tjanstepension's lead in trimming exposure to the stock.